The first-ever randomized controlled trial (RCT) evaluating chimeric antigen receptor (CAR) T cell therapy in solid tumors has shown that the treatment significantly delays disease progression and death versus standard care in patients with gastric or gastroesophageal junction cancer.

“This is the first RCT demonstrating that a CAR-T therapy can outperform chemotherapy in a solid tumor, breaking a long-standing barrier in the field,” said first author Changsong Qi, MD, from Peking University Cancer Hospital & Institute in Beijing, China.

“The treatment, satri-cel, targets a tumor-related antigen, achieves longer survival, and maintains a tolerable safety profile,” noted Qi. “If validated in further studies and real-world settings, this therapy could redefine treatment model, offering a c

See Full Page